Last reviewed · How we verify
NCT04048512
Circulating Tumor Cells (CTC) Before and After Thoracic Resection With and Without Intraoperative Use of ExtraCorporeal Membrane Oxygenator(ECMO) or Cardio Pulmonary By Pass (CPB)
trial testing Resection with intraoperative use of ECMO/CPB in Thoracic Surgery in 20 participants. Status unknown.
22 July 2021
Quick facts
| Lead sponsor | European Institute of Oncology |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 22 August 2019 |
| Primary completion | 22 July 2021 |
| Estimated completion | 30 October 2023 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Resection with intraoperative use of ECMO/CPB
- Resection without intraoperative use of ECMO/CPB
Conditions studied
- Thoracic Surgery — all drugs for Thoracic Surgery →
- Cardiopulmonary Bypass — all drugs for Cardiopulmonary Bypass →
Sponsor
European Institute of Oncology
Who can join
18 and older, any sex, with Thoracic Surgery or Cardiopulmonary Bypass. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The role of circulating tumor cells (CTC) in patients suffering from lung cancer and thoracic malignancies is not well known and it is still widely debated. The use of intraoperative cardiorespiratory supports like ECMO (extracorporeal membrane oxygenator) and CPB (cardiopulmonary by-pass) during extended resections in oncologic patients has been questioned because of the theoretical risk of tumor cells spreading, although there is no clinical or experimental evidence supporting this hypothesis. The aim of the present study is to quantify the possible presence and amount of CTC in the peripheral blood of patients undergoing lung/mediastinal resection, before and after surgical procedure, comparing patients receiving intraoperative cardiorespiratory support with patients - with similar oncologic disease and extension - operated without the need of ECMO or CPB.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.
Janjua D, Chaudhary A, Joshi U, Tripathi T, et al · · 2025 · cited 4× · PMID 40676582 · DOI 10.1186/s12935-025-03883-y -
Intraoperative Extra Corporeal Membrane Oxygenator for Lung Cancer Resections Does Not Impact Circulating Tumor Cells.
Petrella F, Zorzino L, Frassoni S, Bagnardi V, et al · · 2022 · cited 4× · PMID 36291788 · DOI 10.3390/cancers14205004 -
Veno-venous extra-corporeal membrane oxygenation-assisted right tracheal-sleeve pneumonectomy.
Mazzella A, Mazzella A, Bertolaccini L, Petrella F, et al · · 2021 · cited 3× · PMID 33993258 · DOI 10.1093/icvts/ivab124
Verify or expand the search:
- PubMed search for NCT04048512
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thoracic Surgery
Currently open trials in the same condition.
- NCT07392086 — Comparison of FCV and VCV in One-Lung Ventilation · recruiting
- NCT07228598 — Biofilm on Chest Drains After Thoracic Surgery: Clinical Impact and Antibiotic Resistance · recruiting
- NCT07063602 — Sensory Anesthesia Achieved Through Different Paravertebral Block Approaches for Post-Op Pain Management After VATS Lung · recruiting
- NCT06732193 — Fissios© and Postoperative Complications (FPoC Trial) · NA · recruiting
- NCT06417996 — Biobeat Digital Home Monitoring Feasibility · NA · recruiting
Other European Institute of Oncology trials
Trials by the same sponsor.
- NCT07374809 — IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER · NA · not yet recruiting
- NCT07429851 — CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07508319 — Role of the Immune System in Preventing Laryngeal Cancer · recruiting
- NCT07180693 — Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04048512 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by European Institute of Oncology
- Last refreshed: 28 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04048512.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing